1. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. (June 2016) Authors: Signoriello, E; Lanzillo, R; Brescia Morra, V; Di Iorio, G; Fratta, M; Carotenuto, A; Lus, G Journal: Multiple sclerosis Issue: Volume 22:Number 7(2016) Page Start: 921 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗